

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
AJ	AA1	4,675,382	06/23/1987	Murphy	530	350	11/06/1985
	AB1	4,769,326	09/06/1988	Rutter	435	68	04/12/1984
	AC1	4,853,871	08/01/1989	Pantoliano et al.	364	496	04/06/1987
	AD1	4,888,415	12/19/1989	Lambert	530	390	03/07/1988
	AE1	4,894,443	01/16/1990	Greenfield et al.	530	388	09/07/1984
	AF1	4,925,673	05/15/1990	Steiner et al.	424	455	09/08/1987
	AG1	4,946,778	08/07/1990	Ladner et al.	435	69.6	01/19/1989
	AH1	5,013,653	05/07/1991	Huston et al.	435	69.7	12/28/1989
	AI1	5,028,530	07/02/1991	Lai et al.	435	69.1	02/05/1990
	AJ1	5,091,513	02/25/1992	Huston et al.	530	387	01/02/1991
	AK1	5,093,475	03/03/1992	Carroll et al.	530	391.9	12/21/1989

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
AJ	AL1	WO 83/03971	11/24/1983	WIPO		Yes No
	AM1	WO 85/03508	08/15/1985	WIPO		Yes No
	AN1	WO 86/00090	01/03/1986	WIPO		Yes No
	AO1	EP 192 002 A1	08/27/1986	Europe		Yes Abstract No
	AP1	WO 86/05098	09/12/1986	WIPO		Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AJ	AR	1	Antin, J.H., et al., "Selective Depletion of Bone Marrow T Lymphocytes With Anti-CD5 Monoclonal Antibodies: Effective Prophylaxis for Graft-Versus-Host Disease in Patients With Hematologic Malignancies," <i>Blood</i> 78:2139-2149, W. B. Saunders (October 1991).
	AS	1	Asano, K., et al., "Isolation and Characterization of Inhibitors of Animal Cell-Free Protein Synthesis from Barley Seeds," <i>Carlsberg Res. Comm.</i> 49:619-626, Springer-Verlag (1984).
	AT	1	Bacha, P., et al., "Interleukin 2 Receptor-Targeted Cytotoxicity," <i>J. Exp. Med.</i> 167:612-622, The Rockefeller University Press (February 1988).

EXAMINER

AJ

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
As	AA2	5,101,025	03/31/1992	Piatak Jr. et al.	536	27	09/07/1989
	AB2	5,169,939	12/08/1992	Gefter et al.	530	387.3	04/09/1989
	AC2	5,376,546	12/27/1994	Bernhard et al.	435	199	06/19/1992
	AD2	5,416,202	05/16/1995	Bernhard et al.	536	23.2	12/09/1992
	AE2	5,621,083	04/15/1997	Better et al.	530	391.9	04/18/1995
	AF2	5,624,827	04/29/1997	Rosenblum et al.	435	91.5	10/21/1994
	AG2	5,631,348	05/20/1997	Rosenblum et al.	530	370	06/06/1994
	AH2	5,744,580	04/28/1998	Better et al.	530	377	06/07/1995
	AI2	5,756,699	05/26/1998	Better et al.	536	23.4	06/07/1995
	AJ2	5,837,491	11/17/1998	Better et al.	435	69.1	05/13/1996
	AK2	6,146,631	11/14/2000	Better et al.	424	183.1	04/15/1997

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
As	AL2	WO 87/02987	05/21/1987	WIPO	I	I	Yes No
	AM2	EP 0 239 400 A2	09/30/1987	Europe	I	I	Yes No
	AN2	WO 88/01649	03/10/1988	WIPO	I	I	Yes No
	AO2	WO 88/07085	09/22/1988	WIPO	I	I	Yes No
	AP2	WO 88/09344	12/01/1988	WIPO	I	I	Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

As	AR	2	Barry, B.W., ed., in <i>Dermatological Formulations - Percutaneous Absorption</i> , Marcel Decker, Inc., New York, N.Y., pp. 180-181 (1983).
	AS	2	Batra, J.K., et al., "Single-Chain Immunotoxins Directed at the Human Transferrin Receptor Containing <i>Pseudomonas</i> Exotoxin A or Diphtheria Toxin: Anti-TFR(Fv)-PE40 and DT388-Anti-TFR(Fv)," <i>Mol. Cell. Biol.</i> 11:2200-2205, American Society for Microbiology (April 1991).
	AT	2	Batra, J.K., et al., "Anti-Tac(Fv)-PE40, a Single Chain Antibody <i>Pseudomonas</i> Fusion Protein Directed at Interleukin 2 Receptor Bearing Cells," <i>J. Biol. Chem.</i> 265:15198-15202, American Society for Biochemistry and Molecular Biology, Inc. (September 1990).

EXAMINER

As

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0610.099000A	APPLICATION NO. 09/610,838
	APPLICANT Better et al.	
	FILING DATE July 6, 2000	GROUP To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
A	AL3	WO 89/00999	02/09/1989	WIPO	I	I	Yes No
	AM3	AU 27617/88	07/06/1989	Australia	I	I	Yes No
	AN3	WO 89/06967	08/10/1989	WIPO	I	I	Yes No
	AO3	WO 89/06968	08/10/1989	WIPO	I	I	Yes No
	AP3	GB 2,216,891	10/18/1989	Great Britain	I	I	Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

A	AR	3	Benatti, L., et al., "Nucleotide sequence of cDNA coding for saporin-6, a type-1 ribosome-inactivating protein from <i>Saponaria officinalis</i> ," <i>Eur. J. Biochem.</i> 183:465-470, The Federation of American Societies for Experimental Biology (1989).
AS	AS	3	Bernhard, S.L., et al., "Cysteine Analogs of Recombinant Barley Ribosome Inactivating Protein Form Antibody Conjugates with Enhanced Stability and Potency in Vitro," <i>Bioconjugate Chem.</i> 5:126-132, American Chemical Society (March 1994).
AT	AT	3	Better, M., et al., " <i>Escherichia coli</i> Secretion of an Active Chimeric Antibody Fragment," <i>Science</i> 240:1041-1043, Association for the Advancement of Science (May 1988).

EXAMINER A. S.	DATE CONSIDERED 4/1/81
-------------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO..
09/610,838,APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL4	WO 89/09622	10/19/1989	WIPO	I	I	Yes No
	AM4	WO 90/02569	03/22/1990	WIPO	I	I	Yes No
	AN4	WO 90/10015	09/07/1990	WIPO	I	I	Yes No
	AO4	WO 90/12592	11/01/1990	WIPO	I	I	Yes No
	AP4	WO 91/02000	02/21/1991	WIPO	I	I	Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	4	Better, M., et al., "Generation of Potent Immunoconjugates from Microbially Produced Fab', F(ab') ₂ , and Recombinant Ribosome Inactivating Proteins," (Poster), Third Intl. Symposium on Immunotoxins, Orlando, FL (June 1992).
AS	4	Better, M., et al., "Activity of Recombinant Mitogillin and Mitogillin Immunoconjugates," J. Biol. Chem. 267:16712-16718, American Society for Biochemistry and Molecular Biology, Inc. (August 1992).
AT	4	Better, M., et al., "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab') ₂ ," Proc. Natl. Acad. Sci. USA 90:457-461, National Academy of Sciences of the USA (January 1993).


EXAMINER

ANJ

DATE CONSIDERED

4/1/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL5	EP 438 310 A1	07/24/1991	Europe	I	I	Yes No
	AM5	EP 170 697 B1	10/23/1991	Europe	I	I	Yes No
	AN5	WO 91/19745	12/26/1991	WIPO	I	I	Yes No
	AO5	WO 92/03144	03/05/1992	WIPO	I	I	Yes No
	AP5	WO 92/06117	04/16/1992	WIPO	I	I	Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AS	AR	5	Better, M., et al., "Gelonin Analogs with Engineered Cysteine Residues Form Antibody Immunoconjugates with Unique Properties," <i>J. Biol. Chem.</i> 269:9644-9650, American Society for Biochemistry and Molecular Biology, Inc. (April 1994).
	AS	5	Better, M., et al., "T Cell-targeted Immunofusion Proteins from <i>Escherichia coli</i> ," <i>J. Biol. Chem.</i> 270:14951-14957, American Society for Biochemistry and Molecular Biology, Inc. (June 1995).
	AT	5	Blakey, D.C., et al., "Antibody Toxin Conjugates: A Perspective," <i>Monoclonal Antibody Therapy Prog. Allergy</i> 45:50-90, Karger (1988).


EXAMINER

AS

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0610.099000A	APPLICATION NO. 09/610,838
	APPLICANT Better et al.	
	FILING DATE July 6, 2000	GROUP To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
AJ ↓	AL6	WO 92/08495	05/29/1992	WIPO	I	I	Yes
							No
	AM6	WO 92/09613	06/11/1992	WIPO			Yes
							No
	AN6	WO 92/11018	07/09/1992	WIPO			Yes
							No
	AO6	WO 92/14491	09/03/1992	WIPO			Yes
							No
	AP6	WO 92/15327	09/17/1992	WIPO			Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


AJ ↓	AR	6	Bolognesi, A., et al., "A comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating proteins and antibodies," <i>Clin. Exp. Immunol.</i> 89:341-346, Blackwell Scientific Publications (September 1992).
	AS	6	Brown, D., et al., "Customizing Lab Mice," <i>The Washington Post</i> :A1 and A4, <i>The Washington Post</i> (August 21, 1992).
	AT	6	Byers, V.S., et al., "Use of an Anti-Pan T-Lymphocyte Ricin A Chain Immunotoxin in Steroid-Resistant Acute Graft-Versus-Host Disease," <i>Blood</i> 75:1426-1432, W. B. Saunders (April 1990).

EXAMINER AN S	DATE CONSIDERED 4/11/01
------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL7	EP 506 124 A1	09/30/1992	Europe	I	I	Yes No
	AM7	WO 92/22324	12/23/1992	WIPO	I	I	Yes No
	AN7	EP 519 596 A1	12/23/1992	Europe	I	I	Yes No
	AO7	WO 93/05168	03/18/1993	WIPO	I	I	Yes No
	AP7	WO 93/09130	05/13/1993	WIPO	I	I	Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	7	Caron, P.C., et al., "Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies," <i>J. Exp. Med.</i> 176:1191-1195, The Rockefeller University Press (October 1992).
AS	7	Casellas, P., et al., "Optimal Elimination of Leukemic T Cells from Human Bone Marrow With T101-Ricin A-Chain Immunotoxin," <i>Blood</i> 65:289-297, W. B. Saunders (February 1985).
AT	7	Chaudhary, V.K., et al., "A recombinant immunotoxin consisting of two antibody variable domains fused to <i>Pseudomonas</i> exotoxin," <i>Nature</i> 339:394-397, Macmillan Publishers Ltd. (June 1989).

EXAMINER

An S

DATE CONSIDERED 4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>8</u>	Chaudhary, V.K., et al., "A rapid method of cloning functional variable-region antibody genes in <i>Escherichia coli</i> as single-chain immunotoxins," <i>Proc. Natl. Acad. Sci. USA</i> 87:1066-1070, National Academy of Sciences of the USA (February 1990).
	AS	<u>8</u>	Cheadle, C., et al., "Cloning and Expression of the Variable Regions of Mouse Myeloma Protein MOPC315 in <i>E. Coli</i> : Recovery of Active F ₁ Fragments," <i>Mol. Immunol.</i> 29:21-30, Pergamon Press (January 1992).
	AT	<u>8</u>	Chow, T., et al., "Isolation and DNA Sequence of a Gene Encoding α -Trichosanthin, a Type 1 Ribosome-inactivating Protein," <i>J. Biol. Chem.</i> 265:8670-8674, American Society for Biochemistry and Molecular Biology, Inc. (May 1990).

EXAMINER

AN S

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

A1	AR	2	Co, M.S., et al., "Humanized antibodies for antiviral therapy," <i>Proc. Nat. Acad. Sci. USA</i> 88:2869-2873, National Academy of Sciences of the USA (April 1991).
	AS	2	Colombatti, M., et al., "Selective Killing of Target Cells By Antibody-Ricin A Chain or Antibody-Gelolin Hybrid Molecules: Comparison of Cytotoxic Potency and Use in Immunoselection Procedures," <i>J. Immunol.</i> 131:3091-3095, American Association of Immunologists (December 1983).
	AT	2	Delprino, L., et al., "Toxin-Targeted Design for Anticancer Therapy. II: Preparation and Biological Comparison of Different Chemically Linked Gelonin-Antibody Conjugates," <i>Journal of Pharm. Sci.</i> 82:699-704, American Pharmaceutical Association (July 1993).

EXAMINER

A S

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

A ↓	AR	<u>10</u>	Descotes, G., et al., "The Immunological Activity of Plant Toxins Used in the Preparation of Immunotoxins - II. The Immunodepressive Activity of Gelonin," <i>J. Immunopharm.</i> 7:455-463, International Society for Immunopharmacology (1985).
	AS	<u>10</u>	Dower, W.J., et al., "High efficiency transformation of <i>E. coli</i> by high voltage electroporation," <i>Nucleic Acids Res.</i> 16:6127-6145, IRL Press Limited (1988).
	AT	<u>10</u>	Ebert, R.F., and Spryn, L.A., "Immunotoxin Construction with a Ribosome-Inactivating Protein from Barley," <i>Bioconjugate Chem.</i> 1:331-336, American Chemical Society (February 1990).

EXAMINER

A. S.

DATE CONSIDERED 4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AS	AR	<u>11</u>	Ellman, G.L., "Tissue Sulfhydryl Groups," Arch. Biochem. Biophys. 82:70-77, Academic Press (1959).
	AS	<u>11</u>	Fishwild, D.M., et al., "Cytotoxicity against human peripheral blood mononuclear cells and T cell lines mediated by anti-t cell immunotoxins in the absence of added potentiators," Clin. Exp. Immunol. 86:506-513, Blackwell Scientific Publisher (December 1991).
	AT	<u>11</u>	Fishwild, D.M., et al., "Characterization of the increased cytotoxicity of gelonin anti-T cell immunoconjugates compared with ricin A chain immunoconjugates," Clin. Exp. Immunol. 97:10-18, Blackwell Scientific Publications (July 1994).

EXAMINER

AN S

DATE CONSIDERED

4/1/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	12	Glockshuber, R., et al., "A Comparison of Strategies To Stabilize Immunoglobulin F _v -Fragments," <i>Biochem.</i> 29:1362-1367, American Chemical Society (February 1990).
AS	12	Goff, D.A., and Carrol. S.F., "Substituted 2-Iminoethiolanes: Reagents for the Preparation of Disulfide Cross-Linked Conjugates with Increased Stability," <i>Bioconjugate Chem.</i> 1:381-386, American Chemical Society (January 1990).
AT	12	Habuka, N., et al., "Amino Acid Sequence of Mirabilis Antiviral Protein, Total Synthesis of Its Gene and Expression in <i>Escherichia coli</i> ," <i>J. Biol. Chem.</i> 264:6629-6637, American Society for Biochemistry and Molecular Biology, Inc. (April 1989).

EXAMINER

A. S. J.


DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AS	AR	<u>13</u>	Halling, K.C., et al., "Genomic cloning and characterization of a ricin gene from <i>Ricinus communis</i> ," <i>Nucleic Acids Res.</i> 13:8019-8033, IRL Press Limited (1985).
	AS	<u>13</u>	Harris, P., et al., "In Vitro Studies of the Effect of MAb NDA 4 Linked to Toxin on the Proliferation of a Human EBV-Transformed Lymphoblastoid B Cell Line and of Gibbon MLA Leukemia Cell Line," <i>Cell. Immunol.</i> 134:85-95, Academic Press, Inc. (April 1991).
	AT	<u>13</u>	Hertler, A. A., and Frankel, A.E., "Immunotoxins: A Clinical Review of Their Use in the Treatment of Malignancies," <i>J. Clin. Oncol.</i> 7:1932-1943, American Society of Clinical Oncology (December 1989).

EXAMINER

AS


DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT


 PRIORITY DOCKET NO.
0610.099000A

 APPLICATION NO.
09/610,838

 APPLICANT
Better et al.

 FILING DATE
July 6, 2000

 GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AT	AR	14	Ho, W.K.K., et al., "Cloning of the cDNA of α -momorcharin: a ribosome inactivating protein," <i>Biochem. Biophys. Acta</i> 1088:311-314, Elsevier Science Publishers B.V. (February 1991).
	AS	14	Huston, J.S., et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 85:5879-5883, National Academy of Sciences USA (August 1988).
	AT	14	Islam, M.R., et al., "Complete Amino Acid Sequence of Luffin-a, a Ribosome-inactivating Protein from the Seeds of <i>Luffa cylindrica</i> ," <i>Agric. Biol. Chem.</i> 54:1343-1345, Agricultural Chemical Society of Japan (May 1990).

EXAMINER

A. S.


DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
							Yes No
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>15</u>	Izzo, P., et al., "Human aldolase A gene," Eur. J. Biochem. 174:569-578, The Federation of American Societies for Experimental Biology (1988).
	AS	<u>15</u>	Jones, P.J., et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," Nature 321:522-525, Macmillan Publishers Ltd. (May 1986).
	AT	<u>15</u>	Junghans, R.P., et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders," Cancer Res. 50:1495-1502, American Association For Cancer Research (March 1990).

EXAMINER


Apr. 5

DATE CONSIDERED 4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

A ↓	AR	16	Katzin, B.J., et al., "Structure of Ricin A-Chain at 2.5 Å," <i>Proteins: Structure, Function and Genetics</i> 10:251-259, Wiley-Liss, Inc. (June 1991).
	AS	16	Kernan, N.A., et al., "Specific Inhibition of <i>In Vitro</i> Lymphocyte Transformation By An Anti-Pan T Cell (gp67) Ricin A Chain Immunotoxin," <i>J. Immunol.</i> 133:137-146, American Association of Immunologists (July 1984).
	AT	16	Knebel, K.D., et al., "Quantitative Equilibrium Binding of Monoclonal Antibodies, Immunotoxins, and Radioimmunoimaging Agents by Flow Cytometry," <i>Cytometry Suppl.</i> 1:68, Alan R. Liss, Inc. (1987).

EXAMINER


A. J. S.

DATE CONSIDERED 4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT


 PATTY. DOCKET NO.
0610.099000A

 APPLICATION NO.
09/610,838

 APPLICANT
Better et al.

 FILING DATE
July 6, 2000

 GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AS	AR	<u>17</u>	Knowles, P.P., et al., "Purification of Immunotoxins Containing Ricin A-Chain and Abrin A-Chain Using Blue Sepharose CL-6B," Anal. Biochem. 160:440-443, Academic Press, Inc. (1987).
	AS	<u>17</u>	Kohn, F.R., et al., "Efficacy of Anti-CD5 F(AB') ₂ and FAB' Immunoconjugates in Human Peripheral Blood Lymphocyte-Reconstituted Severe Combined Immunodeficient Mice," Int. J. Immunopharmac. 15:871-878, Pergamon Press, Ltd. (November 1993).
	AT	<u>17</u>	Kohr., W.J., et al., "The Amino Acid Sequence of Gelonin." The Protein Society, 4th Symposium, San Diego, CA, Abstract No. T15 (August 1990).

EXAMINER

Ad S

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

APR 10 2001

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned


U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>18</u>	Kong, K., et al., "Subacute Intravenous Toxicity of a Ribosomal Inhibitory Protein, rGelonin, in Rats," (Poster) American College of Toxicology, San Francisco, CA (October 1992).
	AS	<u>18</u>	Kung, S.-S., "The Complete Amino Acid Sequence of Antiviral Protein from the Seeds of Pokeweed (<i>Phytolacca americana</i>)," <i>Agric. Biol. Chem.</i> 54:3301-3318, Agricultural Chemical Society of Japan (September 1990).
	AT	<u>18</u>	Lambert, J.M., et al., "Purified Immunotoxins That Are Reactive with Human Lymphoid Cells," <i>J. Biol. Chem.</i> 260:12035-12041, American Society for Biochemistry and Molecular Biology, Inc. (October 1985).

EXAMINER

A.S.

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

A1	AR	<u>19</u>	Laurent, G., et al., "Donor bone marrow treatment with T101 Fab fragment-ricin A-chain immunotoxin prevents graf-versus-host disease," <i>Bone Marrow Transplantation</i> 4:367-371, Macmillan Press Ltd. (1989).
	AS	<u>19</u>	Lee-Huang, S., et al., "A new class of anti-HIV agents: GAP31, DAPs 30 and 32," <i>FEBS</i> 291:139-144, Elsevier Science Publishers B.V. (October 1991).
	AT	<u>19</u>	Li, S.S.-L., et al., "Purification and partial characterization of two lectins from <i>Momordica charantia</i> ," <i>Experientia</i> 36:524-527, Birkhäuser Verlag (1980).


EXAMINER

A N S

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AS	AR	20	Madan, S., and Ghosh, P.C., "Interaction of Gelonin With Macrophages: Effect of Lysosomotropic Amines," <i>Exper. Cell Res.</i> 198:52-58, Academic Press, Inc. (January 1992).
	AS	20	Montecucchi, P.C., et al., "N-terminal sequence of some ribosome-inactivating proteins," <i>Int. J. Peptide Protein Res.</i> 33:263-267, Munksgaard (1989).
	AT	20	Morishima, Y., et al., "Functionally Different T Lymphocyte Subpopulations Determined By Their Sensitivity to Complement-Dependent Cell Lysis With the Monoclonal Antibody 4A," <i>J. Immunol.</i> 129:1091-1098, American Association of Immunologists (September 1982).

EXAMINER

AMS

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>21</u>	Mountain, A., and Adair, J.A., "Engineering Antibodies for Therapy," in <i>Biotechnology and Genetic Engineering Reviews</i> 10:1-142, Intercept Ltd., Andover, U.K. (December 1992).
	AS	<u>21</u>	Munson, P.J., et al., "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems," <i>Anal. Biochem.</i> 107:220-239, Academic Press, Inc. (1980).
	AT	<u>21</u>	Myers, E.W., and Miller, W., "Optimal alignments in linear space," <i>Cabios Commun.</i> 4:11-17, IRL Press Limited (1988).

EXAMINER

AN 5

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

APR 10 2001

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	22	Nolan, P.A., et al., "Cloning and expression of a gene encoding gelonin, a ribosome-inactivating protein from <i>Gelonium multiflorum</i> ," <i>Gene</i> 134:223-227, Elsevier Science Publishers B.V. (December 1993).
	AS	22	Ogata, M., et al., "Processing of <i>Pseudomonas</i> Exotoxin by a Cellular Protease Results in the Generation of a 37,000-Da Toxin Fragment That is Translocated to the Cytosol," <i>J. Biol. Chem.</i> 265:20678-20685, American Society for Biochemistry and Molecular Biology, Inc. (November 1990).
	AT	22	Oldham, R.K., et al., "Adriamycin custom-tailored immunoconjugates in the treatment of human malignancies," <i>Mol. Biother.</i> 1:103-113, Butterworth Publishers (1988).

EXAMINER

An S

DATE CONSIDERED 4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AS	AR	23	O'Hare, M., et al., "Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence," <i>FEBS Lett.</i> 273:200-204, Elsevier Science Publishers B.V. (October 1990).
	AS	23	Pastan, I., and FitzGerald, D., "Recombinant Toxins for Cancer Treatment," <i>Science</i> 254:1173-1177, Association for the Advancement of Science (November 1991).
	AT	23	Potter, H., et al., "Enhancer-dependent expression of human κ immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation," <i>Proc. Natl. Acad. Sci. USA</i> 81:7161-7165, National Academy of Sciences of the USA (November 1984).

EXAMINER

AS


DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
							Yes
	AL						No
							Yes
	AM						No
							Yes
	AN						No
							Yes
	AO						No
							Yes
	AP						No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	24	Preijers, F.W.M.B., et al., "Autologous Transplantation of Bone Marrow Purged In Vitro With Anti-CD7-(WT1-) Ricin A Immunotoxin in T-Cell Lymphoblastic Leukemia and Lymphoma," <i>Blood</i> 74:1152-1158, Grune & Stratton, Inc. (August 1989).
AS	24	Press, O.W., et al., "A simplified microassay for inhibition of protein synthesis in reticulocyte lysates by immunotoxins," <i>Immunol. Letters</i> 14:37-41, Elsevier Science Publishers B.V. (1986).
AT	24	Queen, C., et al., "A humanized antibody that binds to the interleukin 2 receptor," <i>Proc. Natl. Acad. Sci. USA</i> 86:10029-10033, National Academy of Sciences of the USA (December 1989).

EXAMINER

AR


DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
							Yes No
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>25</u>	Ready, M., et al., "Ricin-like Plant Toxins are Evolutionarily Related to Single-chain Ribosome-inhibiting Proteins from <i>Phytolacca</i> ," <i>J. Biol. Chem.</i> 259:15252-15256, American Society of Biological Chemists, Inc. (December 1984).
	AS	<u>25</u>	Reimann, K. A., et al., "In Vivo Administration of Lymphocyte-specific Monoclonal Antibodies in Nonhuman Primates," <i>J. Clin. Invest.</i> 82:129-138, American Society for Clinical Investigation, Inc. (July 1988).
	AT	<u>25</u>	Riechmann, L., et al., "Reshaping human antibodies for therapy," <i>Nature</i> 322:323-327, Macmillan Publishers Ltd. (March 1988).

EXAMINER

DATE CONSIDERED

9/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

APR 10 2001

ATTY. DOCKET NO.
#610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	26	Robinson, R.R., et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," <i>Human Antibod. and Hybridomas</i> 2:84-93, Butterworth-Heinemann (April 1991).
AS	26	Rosenblum, M.G., et al., "A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin," <i>Mol. Biother.</i> 3:6-13, Butterworth-Heinemann (March 1991).
AT	26	Rostaing-Capaillon, O., and Casellas, P., "In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain," <i>Cancer Immunol. Immunother.</i> 34:24-30, Springer-Verlag (January 1991).


EXAMINER

An

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTPAT. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

A ↓	AR	27	Rowley, S.D., et al., "Efficacy of Ex Vivo Purging for Autologous Bone Marrow Transplantation in the Treatment of Acute Nonlymphoblastic Leukemia," <i>Blood</i> 74:501-506, Grune & Stratton, Inc. (July 1989).
	AS	27	Royston, I., et al., "Human T Cell Antigens Defined By Monoclonal Antibodies: The 65,000-Dalton Antigen of T Cells (T65) Is Also Found On Chronic Lymphocytic Leukemia Cells Bearing Surface Immunoglobulin," <i>J. Immunol.</i> 125:725-731, The Williams & Wilkins Co. (August 1980).
	AT	27	Scott, C.F., et al., "The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin," <i>Cancer Immunol. Immunother.</i> 25:31-40, Springer-Verlag (July 1987).

EXAMINER

Ar 8


DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT


 PRIORITY DOCKET NO.
0610.099000A

 APPLICATION NO.
09/610,838

 APPLICANT
Better et al.

 FILING DATE
July 6, 2000

 GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AS	AR	28	Shaw, P.-C., et al., "Cloning of trichosanthin cDNA and its expression in <i>Escherichia coli</i> ," Gene 97:267-272, Elsevier (January 1991).
	AS	28	Singh, V., and Curtiss III, R., "Hormonotoxins: Abrogation of Ribosome Inactivating Property of Gelonin in the Disulfide Linked Ovine Luteinizing Hormone-Gelonin Conjugates," Biochem. Intl. 25:531-536, Academic Press Australia (October 1991).
	AT	28	Sivam, G., et al., "Immunotoxins to a Human Melanoma-associated Antigen: Comparison of Gelonin With Ricin and Other A Chain Conjugates," Cancer Res. 47:3169-3173, American Association For Cancer Research (June 1987).

EXAMINER

AN

DATE CONSIDERED

9/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

 PATENT & TRADEMARK OFFICE
 APR 10 2001
 STPE

 PAT. DOCKET NO.
 0610.099000A

 APPLICATION NO.
 09/610,838

 APPLICANT
 Better et al.

 FILING DATE
 July 6, 2000

 GROUP
 To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	29	Sperti, S., et al., "Requirements for the inactivation of ribosomes by gelonin," Biochem. J. 227:281-284, London Portland Press On Behalf Of The Biochemical Society (July 1991).
	AS	29	Stirpe, F., et al., "Gelonin, a New Inhibitor of Protein Synthesis, Nontoxic to Intact Cells," J. Biol. Chem. 255:6947-6953, American Society for Biochemistry and Molecular Biology, Inc. (July 1980).
	AT	29	Stirpe, F., et al., "Ribosome-inactivating proteins up to date," FEBS Lett. 195:1-8, Elsevier Science Publishers B.V. (January 1986).

EXAMINER

Am S

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>30</u>	Stirpe, F., et al., "Modification of ribosomal RNA by ribosome-inactivating proteins from plants," <i>Nucleic Acids Research</i> , 16:1349-1357, IRL Press Limited (February 1988).
	AS	<u>30</u>	Strockbine, N.A., et al., "Cloning and Sequencing of the Genes for Shiga Toxin from <i>Shigella dysenteriae</i> Type 1," <i>J. Bacteriol.</i> 170:1116-1122, American Society for Microbiology (1988).
	AT	<u>30</u>	Thorpe, P.E., et al., "New Coupling Agents for the Synthesis of Immunotoxins Containing a Hindered Disulfide Bond with Improved Stability <i>in Vivo</i> ," <i>Cancer Res.</i> 47:5924-5931 (1987).

EXAMINER

AR 5

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AS	AR	<u>31</u>	Thorpe, P.E., et al., "Improved Antitumor Effects of Immunotoxins Prepared with Deglycosylated Ricin A-Chain and Hindered Disulfide Linkages," <i>Cancer Res.</i> 48:6396-6403, American Association For Cancer Research (November 1988).
	AS	<u>31</u>	Tolan, D.R., et al., "The Complete Nucleotide Sequence for Rabbit Muscle Aldolase A Messenger RNA," <i>J. Biol. Chem.</i> 259:1127-1130, American Society for Biochemistry and Molecular Biology, Inc. (1984).
	AT	<u>31</u>	Vallera, D.A., "Immunotoxins: Will Their Clinical Promise Be Fulfilled?" <i>Blood</i> 83:309-317, American Society for Hematology (January 1994).

EXAMINER

AN S

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0650.099000AAPPLICATION NO.
09/610,838APPLICANT
Letter et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>32</u>	Wawrzynczak, E.J., et al., "Pharmacokinetics in the Rat of a Panel of Immunotoxins Made With Abrin A Chain, Ricin A Chain, Gelonin, and Momordin," <i>Cancer Res.</i> 50:7519-7526, American Association For Cancer Research (December 1990).
	AS	<u>32</u>	Westby, M., et al., "Preparation and Characterization of Recombinant Proricin Containing an Alternative Protease-Sensitive Linker Sequence," <i>Bioconjugate Chem.</i> 3:375-381, American Chemical Society (September 1992).
	AT	<u>32</u>	Williams, D.P., et al., "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein," <i>Protein Engineering</i> 1(6):493-498, Oxford University Press (1987).

EXAMINER

AJS


DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0610.099000AAPPLICATION NO.
09/610,838APPLICANT
Better et al.FILING DATE
July 6, 2000GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	33	Dialog File 351, Derwent World Patents Index, English Language abstract for EP 192002 A1, WPI Accession No. 86-226683
AS	33	
AT	33	

EXAMINER

Ans

DATE CONSIDERED

4/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.